A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

NCT ID: NCT01525017

Last Updated: 2015-10-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-02-29
• Study Completion Date: 2013-12-31

Brief Summary

The primary objective of this study is to answer the question "Is it possible to inject the Combig-DC vaccine in a renal tumour without getting unacceptable side effects"? Patients newly diagnosed with metastatic renal cell carcinoma will get Combig-DC vaccinations at two occasions in a two weeks period (day 1 and day 14). After another two weeks the kidney will be eliminated. Adverse events will be registered, as well as changes in vital signs(heart rate, blood pressure and body temperature) and lab parameters. Immunologic response will be evaluated by measuring immunologic markers in blood and tumour tissue, and measuring the size of the metastases three months after nephrectomy.

Conditions

Metastatic Renal Cell Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Combig-DC Cancer Vaccine

Two vaccinations of Combig-DC (allogeneic dendritic cells) Cancer Vaccine given before nephrectomy.

Group Type: EXPERIMENTAL

Combig-DC (allogeneic dendritic cells) Cancer Vaccine

Intervention Type: BIOLOGICAL

Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).

Interventions

Combig-DC (allogeneic dendritic cells) Cancer Vaccine

Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Be informed of the nature of the study and have provided written informed consent

2. At least 18 years of age.

3. Diagnosis of renal cell carcinoma with at least one distant metastasis, and/or one distant lymph node metastasis.

4. Tumor size (renal cell carcinoma; primary tumor) at least 4.0 cm in longest diameter as measured by CT. Distant metastasis at least 1 cm diameter as measured by CT or a distant lymph node metastasis at least 2,5 cm diameter as measured by CT. Clinical stage 'T1b or more; NX; M1'

5. Adequate hematological parameters, i.e:

B-Leukocyte count ≥ 4.5 x 109/L B-Platelet count ≥ 150 x109/L B-Haemoglobin ≥ 100 g/L

6. Women of Childbearing Potential (WOCBP) should use adequate contraception (oral or injectable contraceptives, hormone releasing intrauterine device) throughout the study period.

Exclusion Criteria

1. Performance status > ECOG 2 after optimization of analgesics

2. Adequate coagulation parameters, i.e: P-Prothrombin complex (PK), P-APT time

3. Ongoing treatment with systemic corticosteroids (inhaled, intranasal and local steroids accepted) within 28 days before first vaccination.

4. Previously known or ongoing active autoimmune disease which requires treatment with systemic immunosuppressive agents. E.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis, autoimmune hemolytic anemia, rheumatoid arthritis, SLE, vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other rheumatological diseases.

5. Patients with previous or ongoing skin malignancy (basal-cell carcinoma, squamous cell carcinoma, melanoma), other hematological or solid malignancy or blood dysfunctions.

6. Ongoing infection that requires treatment with antibiotics.

7. Known major reaction/adverse event in connection with previously made vaccination (e.g. asthma, anaphylaxis or other serious reaction)

8. Known malignancy in CNS.

9. Active or latent virus disease (HIV, HBV and HCV).

10. Ongoing pregnancy or lactation. Females needs to have negative pregnancy test at screening visit.

11. Life expectancy less than 3 months.

12. Concomitant exposure to other investigational products.

13. Any reason that, in the opinion of the investigator, contraindicates that the patient participates in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mendus

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anna Laurell, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Dept of Oncology , Uppsala University Hospital

Locations

Dept of Oncology, University Hospital

Uppsala, , Sweden

Countries

Sweden

References

Laurell A, Lonnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren AC, Andersson B, Adamson L, Kiessling R, Karlsson-Parra A. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J Immunother Cancer. 2017 Jun 20;5:52. doi: 10.1186/s40425-017-0255-0. eCollection 2017.

Reference Type: DERIVED

PMID: 28642820 (View on PubMed)

Other Identifiers

2011-002039-25

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

IM-101

Identifier Type: -

Identifier Source: org_study_id